Pricing

Aeterna Zentaris Inc (AEZS)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Klaus W. Paulini
Employees:
20
C/O NORTON ROSE FULBRIGHT CANADA LLP, 222 BAY STREET, SUITE 3000, PO BOX 53, TORONTO, A6, M5K 1E7
843-900-3201
Stock Split History
DateRatio
2012-10-05 1:6
2015-11-20 1:100
2022-07-21 1:25
2024-05-03 1:4
Aeterna Zentaris Inc. engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR 1a. The company has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available